Telomir Pharmaceuticals, Inc. (TELO) Current Ratio
- Current ratio · latest quarter: Value 16.14×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.14× | Current assets / current liabilities. $5.37M ÷ $332.42K ≈ 16.14× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 5.37M USD | Assets, Current |
| Current obligations | 332.42K USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.37M | $332.42K | (m) | (m) | (m) | (m) | (m) | (m) | 16.14× |
| 2026-03-31 | $5.79M | $827.31K | (m) | (m) | (m) | (m) | (m) | (m) | 7.00× |
| 2025-12-31 | $7.34M | $1.43M | (m) | (m) | (m) | (m) | (m) | (m) | 5.14× |
| 2025-09-30 | $7.40M | $422.81K | (m) | (m) | (m) | (m) | (m) | (m) | 17.51× |
| 2025-06-30 | $829.61K | $348.39K | $754.32K | (m) | (m) | (m) | (m) | (m) | 2.38× |
| 2025-03-31 | $491.19K | $652.29K | $403.00K | (m) | (m) | (m) | (m) | (m) | 0.75× |
| 2024-12-31 | $1.32M | $680.97K | (m) | (m) | (m) | (m) | (m) | (m) | 1.94× |
| 2024-09-30 | $1.04M | $599.91K | (m) | (m) | (m) | (m) | (m) | (m) | 1.74× |
| 2024-06-30 | $2.10M | $534.15K | (m) | (m) | (m) | (m) | (m) | (m) | 3.93× |
| 2024-03-31 | $3.50M | $486.55K | (m) | (m) | (m) | (m) | (m) | (m) | 7.20× |
| 2023-12-31 | $435.23K | $1.34M | (m) | (m) | (m) | (m) | (m) | (m) | 0.33× |
| 2022-12-31 | $48.73K | $986.01K | (m) | (m) | (m) | (m) | (m) | (m) | 0.05× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |